In the Wuhan Province of China, in December 2019, the novel coronavirus 2019
(COVID-19) has caused a severe involvement of the lower respiratory tract leading
to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2)
provoked a pandemic which is considered a life-threatening disease. The
SARS-CoV-2, a family member of betacoronaviruses, possesses single-stranded
positive-sense RNA with typical structural proteins, involving the envelope,
membrane, nucleocapsid and spike proteins that are responsible for the viral
infectivity, and nonstructural proteins. The effectual host immune response
including innate and adaptive immunity against SARS-Cov-2 seems crucial to
control and resolve the viral infection. However, the severity and outcome of the
COVID-19 might be associated with the excessive production of proinflammatory
cytokines “cytokine storm” leading to an acute respiratory distress syndrome.
Regretfully, the exact pathophysiology and treatment, especially for the severe
COVID-19, is still uncertain. The results of preliminary studies have shown that
immune-modulatory or immune-suppressive treatments such as
hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in
rheumatology, might be considered as treatment choices for COVID-19, particularly
in severe disease. In this review, to gain better information about appropriate
anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we
have focused the attention on the structural features of SARS-CoV-2, the host
immune response against SARS-CoV-2 and its association with the cytokine storm

제 1편 코로나바이러스 정의
1. 코로나바이러스감염증-19(Covid-19) 정보 7
2. 코로나바이러스 분류 및 특성 9
3. 코로나바이러스 전자현미경 형태 11
4. 코로나바이러스 구조 (Covid-19 Organization) 13
5. 코로나19: 환경에 지속적인 영향을 미칠까? 19
6. 치료법(Therapeutical Method) 22

제 2편 연구논문
COVID-19, immune system response, hyperinflammation and
repurposing antirheumatic drugs

1. Introduction 23
2. The origin and structural features of SARS-CoV2 23
3. The immune response and cytokine storm in COVID-19 24
4. Potential antiinflammatory treatments used in Rheumatology
for COVID-19 27
5. Conclusions 31
6. References 31